How will mitomycin C shortages affect glaucoma surgery?
Obeda Kailani, Claudia Quijano, Dan Lindfield | | Longer Read
Europe and Asia are currently afflicted by a sudden availability crisis of mitomycin C (MMC). This is significant as the majority of trabeculectomy procedures performed in modern times utilize antimetabolites, and 63 percent of those use MMC (1). After an issue with the sterile processing of the drug was detected, Kyowa Kirin – a Japanese pharmaceutical and biotechnology company – ceased production of MMC pending investigation, and a Class 2 product recall of all shelf stock is currently underway. In the UK, Kyowa Kirin’s drug is the only MMC product licensed for ophthalmic use. MMC licensed for intravesical application is still available in theory but supply is taken up by urological cancer requirements, leaving no surplus. Other routes of non-licensed supply were available, but the instant surge in demand meant those were quickly exhausted. This has left the UK, Europe and parts of Asia with no access to MMC, and hence trabeculectomy, tube shunt surgery and sub-conjunctival MIGS procedures (such as XEN or PRESERFLO) face significant challenges. The effects are expected to last at least until spring 2020.
Read the full article now
Log in or register to read this article in full and gain access to The Ophthalmologist’s entire content archive. It’s FREE and always will be!
Or register now - it’s free and always will be!
You will benefit from:
- Unlimited access to ALL articles
- News, interviews & opinions from leading industry experts
- Receive print (and PDF) copies of The Ophthalmologist magazine
Or Login via Social Media
By clicking on any of the above social media links, you are agreeing to our Privacy Notice.